Skip to main content

Table 4 Baseline characteristics of subjects with and without subsequent fracture

From: The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies

 FREEDOM analysis (3 years)FREEDOM + Extension analysis (10 years)
Subjects with subsequent fractureSubjects without subsequent fractureSubjects with subsequent fractureSubjects without subsequent fracture
Placebo N = 54Denosumab N = 24Placebo N = 384Denosumab N = 248Combined denosumab N = 144Combined denosumab N = 650
Age at the beginning of treatment, years72.1 (5.4)73.5 (6.0)72.8 (5.3)73.1 (5.1)73.2 (5.0)73.2 (5.1)
Age at first incident fracture, years73.2 (5.7)74.7 (6.0)74.3 (5.4)74.5 (5.2)76.1 (5.1)76.6 (5.4)
Prior osteoporotic fracture before treatment, n (%)45 (83.3)18 (75.0)210 (54.7)142 (57.3)94 (65.3)352 (54.2)
Baseline vertebral fracture before treatment, n (%)29 (53.7)14 (58.3)116 (30.2)89 (35.9)60 (41.7)201 (30.9)
Total hip BMD T-score at the beginning of treatment− 2.34 (0.77)− 2.42 (0.75)− 2.12 (0.81)− 2.09 (0.80)− 2.02 (0.82)− 2.03 (0.82)
Closest total hip BMD T-score during treatment prior to first incident fracture− 2.29 (0.84)− 2.43 (0.97)− 2.11 (0.81)− 1.91 (0.81)− 1.74 (0.88)− 1.70 (0.86)
Treatment duration prior to first incident fracture, median (Q1, Q3), years1.02 (0.52, 1.96)0.87 (0.54, 1.27)1.40 (0.84, 2.01)1.25 (0.66, 2.13)2.21 (1.01, 4.81)2.82 (1.26, 5.03)
  1. Data are mean (standard deviation) unless otherwise noted
  2. N subjects who received ≥ 2 doses of investigational product, had an osteoporotic fracture on treatment, and remained on study post-fracture, n number of subjects, BMD bone mineral density, Q1, Q3 quartiles 1 and 3